Akeso, Inc. (HKG:9926)
Hong Kong · Delayed Price · Currency is HKD 105.20
-0.10 (-0.09%)
Feb 16, 2026, 12:08 PM HKT
Akeso Employees
Akeso had 3,529 employees as of June 30, 2025. The number of employees increased by 494 or 16.28% since the number was reported on December 31, 2024.
Employees
3,529
Change
494
Growth
16.28%
Revenue / Employee
779.60K HKD
Profits / Employee
-262.69K HKD
Market Cap
96.90B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 3,529 | 494 | 16.28% |
| Dec 31, 2024 | 3,035 | 257 | 9.25% |
| Dec 31, 2023 | 2,778 | 437 | 18.67% |
| Dec 31, 2022 | 2,341 | 476 | 25.52% |
| Dec 31, 2021 | 1,865 | 1,119 | 150.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 23,056 |
| WuXi Biologics | 12,552 |
| BeOne Medicines AG | 11,000 |
| 3SBio | 6,268 |
| Innovent Biologics | 6,190 |
| Shanghai Henlius Biotech | 3,537 |
| RemeGen | 3,070 |
| Shanghai Junshi Biosciences | 2,670 |
Akeso News
- 4 weeks ago - Akeso's Cadonilimab Outperforms PD-1 Inhibitors In Gastric Cancer; Stock Up - Nasdaq
- 5 weeks ago - Akeso Secures NMPA Label Update For Ivonescimab With Dual Survival Benefits In NSCLC - Nasdaq
- 2 months ago - Akeso Presents Positive Data Of Cadonilimab Regimen In Resectable Gastric Cancer At ESMO Asia 2025 - Nasdaq
- 3 months ago - Summit C-Suite Risks Success, Akeso Wins Either Way - Seeking Alpha
- 3 months ago - Akeso, Inc. (AKESF) Presents at 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) - Slideshow - Seeking Alpha
- 4 months ago - Akeso, Inc. (AKESF) Presents at ESMO Congress 2025 - Slideshow - Seeking Alpha
- 4 months ago - China’s Akeso gets share boost as data shows cancer drug’s benefits - South China Morning Post
- 5 months ago - Akeso's Ligufalimab Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia - Nasdaq